Repeated Low-Level Red-Light Intervention Prevents Myopia in Children
26 Apr 2023
Clinical Result
WEDNESDAY, April 26, 2023 -- A repeated low-level, red-light (RLRL) intervention is effective for preventing myopia among children with premyopia, according to a study published online April 26 in JAMA Network Open.
Xiangui He, Ph.D., from the Shanghai Eye Hospital, and colleagues conducted a 12-month school-based randomized clinical trial involving children in grades 1 to 4 with premyopia to examine the efficacy and safety of an RLRL intervention for preventing incident myopia. Children in the intervention group received RLRL therapy twice per day, five days per week, while those in the control group continued usual activities (139 children in each group).
The researchers found that the 12-month incidence of myopia was 40.8 and 61.3 percent in the intervention and control groups, respectively, representing a 33.4 percent reduction in incidence. Children in the intervention group who did not have treatment interruption secondary to the COVID-19 pandemic had an incidence of 28.1 percent, representing a 54.1 percent reduction in incidence. Significant reductions in myopic shifts in terms of axial length and cycloplegic spherical equivalence refraction were seen with the RLRL intervention (mean, 0.30 versus 0.47 mm; and −0.35 versus −0.76 D, respectively). On optical coherence tomography scans, there was no visual acuity or structural damage noted in the intervention group.
"Our findings have public health significance, especially for myopia prevention in countries with a high incidence of myopia," the authors write. "More studies are needed to understand the long-term efficacy and safety, optimal intervention dose, and potential underlying mechanisms of the RLRL intervention."
Two authors have a patent pending; one reported financial ties to Eyerising Ltd. and Eyerising International Pty Ltd.
Abstract/Full Text
Posted April 2023
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.